Crispr Therapeutics reports Q4 EPS ($1.41) vs. ($1.84) y/y

Yesterday evening, the company also reported its Q4 revenue at $6K vs. $12.9M y/y. Cash, cash equivalents and marketable securities were $1,868.4 million as of December 31, 2022, compared to $2,379.1 million as of December 31, 2021. The decrease in cash of $510.7 million was "primarily driven by cash used in operating activities to support ongoing research and development." "2022 marked a significant year of progress toward our goal of delivering innovative gene edited therapies to patients. Exa-cel has the potential to be the first approved CRISPR-based therapy in the world, with regulatory submissions complete in Europe and underway in the United States," said Samarth Kulkarni, CEO of CRISPR Therapeutics. "At the same time, we continue to expand our pipeline and drive forward our programs across the immuno-oncology, diabetes and cardiovascular disease verticals. Based on encouraging data reported in 2022 at EHA and ASH conferences, we continue to advance both CTX110 and CTX130 in larger clinical trials. We are also initiating clinical trials for our next generation CAR T cell programs, CTX112 and CTX131, which have the potential to be best-in-class cell therapies. We continue to progress our regenerative medicine portfolio with the advancement of VCTX211, an immune-evasive cell replacement therapy designed to enable patients with T1D to produce their own insulin, to the clinic following clearance of our CTA by Health Canada. Finally, we expect to move our first in vivo program, CTX310, into the clinic this year, while advancing additional in vivo programs into IND-enabling studies. We are well-positioned to continue expanding our portfolio of transformative medicines while continuously improving our editing and delivery platform throughout 2023."